Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management

Aslan, Anolin; Aslan, Cynthia; Zolbanin, Naime Majidi; Jafari, Reza

doi:10.1186/s41479-021-00092-9

Cited by 93 publications

(101 citation statements)

References 114 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…Therefore, controlling the development of ARDS may also be a feasible treatment strategy for COVID-19. At present, a number of clinical studies (NCT04244591/NCT04327401/NCT04476992/NCT04306393…) are using strategies such as glucocorticoids, small molecule drugs, recombinant interferon and NO inhalation to explore the effectiveness of intervening in ARDS to affect COVID-19 ( 266 , 267 ). Perhaps this strategy will provide more evidence for the safety and efficacy of treating COVID-19.…”

Section: Potential Therapeutic Strategies and Promising Anti-sars-cov...mentioning

confidence: 99%

Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19

Zhou

Huang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

As the new year of 2020 approaches, an acute respiratory disease quietly caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19) was reported in Wuhan, China. Subsequently, COVID-19 broke out on a global scale and formed a global public health emergency. To date, the destruction that has lasted for more than two years has not stopped and has caused the virus to continuously evolve new mutant strains. SARS-CoV-2 infection has been shown to cause multiple complications and lead to severe disability and death, which has dealt a heavy blow to global development, not only in the medical field but also in social security, economic development, global cooperation and communication. To date, studies on the epidemiology, pathogenic mechanism and pathological characteristics of SARS-CoV-2-induced COVID-19, as well as target confirmation, drug screening, and clinical intervention have achieved remarkable effects. With the continuous efforts of the WHO, governments of various countries, and scientific research and medical personnel, the public’s awareness of COVID-19 is gradually deepening, a variety of prevention methods and detection methods have been implemented, and multiple vaccines and drugs have been developed and urgently marketed. However, these do not appear to have completely stopped the pandemic and ravages of this virus. Meanwhile, research on SARS-CoV-2-induced COVID-19 has also seen some twists and controversies, such as potential drugs and the role of vaccines. In view of the fact that research on SARS-CoV-2 and COVID-19 has been extensive and in depth, this review will systematically update the current understanding of the epidemiology, transmission mechanism, pathological features, potential targets, promising drugs and ongoing clinical trials, which will provide important references and new directions for SARS-CoV-2 and COVID-19 research.

show abstract

Section: Potential Therapeutic Strategies and Promising Anti-sars-cov...mentioning

confidence: 99%

Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19

Zhou

Huang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Before COVID-19, ARDS affected 200 000 individuals annually in the USA, with a mortality rate of approximately 40% [ 2 ]. The incidence of ARDS increased substantially with COVID-19, with 30% of COVID patients admitted to hospital having ARDS of which 75% were admitted to the intensive care unit [ 3 ]. ARDS mortality is strongly associated with ventilator-induced lung injury (VILI), potentially due to the interactions between micro- and macroscale elements of the lung [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Computational lung modelling in respiratory medicine

Neelakantan

Xin

Gaver

et al. 2022

J. R. Soc. Interface.

View full text Add to dashboard Cite

Computational modelling of the lungs is an active field of study that integrates computational advances with lung biophysics, biomechanics, physiology and medical imaging to promote individualized diagnosis, prognosis and therapy evaluation in lung diseases. The complex and hierarchical architecture of the lung offers a rich, but also challenging, research area demanding a cross-scale understanding of lung mechanics and advanced computational tools to effectively model lung biomechanics in both health and disease. Various approaches have been proposed to study different aspects of respiration, ranging from compartmental to discrete micromechanical and continuum representations of the lungs. This article reviews several developments in computational lung modelling and how they are integrated with preclinical and clinical data. We begin with a description of lung anatomy and how different tissue components across multiple length scales affect lung mechanics at the organ level. We then review common physiological and imaging data acquisition methods used to inform modelling efforts. Building on these reviews, we next present a selection of model-based paradigms that integrate data acquisitions with modelling to understand, simulate and predict lung dynamics in health and disease. Finally, we highlight possible future directions where computational modelling can improve our understanding of the structure–function relationship in the lung.

show abstract

“…Given the mutations, the persistent infection in the population has been unprecedented; the lack of vaccination is another cause ( 2 ), such that massive death tolls have been reported on a real-time basis by the World Health Organization ( ). Some COVID-19 cases are accompanied by mortiferous symptoms, including acute respiratory distress ( 3 ). It has been observed that infection in patients with cancer with SARS-CoV-2 is more severe than in healthy patients ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Preclinical In Silico Evidence Indicates the Pharmacological Targets and Mechanisms of Mogroside V in Patients With Ovarian Cancer and Coronavirus Disease 2019

Chen

Wei

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

The borderless transmission of coronavirus remains uncontrolled globally. The uncharted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant reduces the therapeutic efficacy of vaccines against coronavirus disease 2019 (COVID-19). Clinical observations suggest that tumour cases are highly infected with coronavirus, possibly due to immunologic injury, causing a higher COVID-19-related death toll. Presently, screening of candidate medication against coronavirus is in progress. Mogroside V, a bioactive ingredient of Siraitia grosvenorii, has been reported in China to have lung-protective and anticancer effects. The current study used network pharmacology and molecular docking to unlock the potential drug targets and remedial mechanisms of mogroside V against patients with ovarian cancer with COVID-19. We identified 24 related targets of mogroside V in patients with ovarian cancer and COVID-19 and characterised another 10 core targets of mogroside V against COVID-19 ovarian cancer, including Jun, IL2, HSP90AA1, AR, PRKCB, VEGFA, TLR9, TLR7, STAT3, and PRKCA. The core targets’ biological processes and signalling pathways were revealed by enrichment analysis. Molecular docking suggested favourable docking between core target protein and mogroside V, including vascular endothelial growth factor A (VEGFA). These findings indicated that mogroside V might be a potential therapeutic agent in the mitigation of COVID-19 ovarian cancer.

show abstract

Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management

Cited by 93 publications

References 114 publications

Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19

Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19

Computational lung modelling in respiratory medicine

Preclinical In Silico Evidence Indicates the Pharmacological Targets and Mechanisms of Mogroside V in Patients With Ovarian Cancer and Coronavirus Disease 2019

Contact Info

Product

Resources

About